Isomorphic Labs raises $5 billion for AI drug discovery
Tech

Isomorphic Labs raises $5 billion for AI drug discovery

TechNews Editorial
TechNews EditorialNov 17, 2026 · 1 min read
Share

Why it matters

The $5 billion round funds Isomorphic Labs’ drug design platform and pipeline as the company works toward clinical trials without an approved drug.

The facts

  • Isomorphic Labs raised $5 billion in its second billion-dollar round in six months.
  • The company plans to advance IsoDDE and push its drug pipeline toward clinical trials.
  • Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug yet.

Advertisement

Alphabet’s AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar funding round in six months. Greenoaks and Sequoia Capital co-led the round. New backer Andreessen Horowitz joined Alphabet and all existing investors.

Isomorphic Labs raised $2.1 billion in May 2026. It plans to use the new funding to advance its in-house platform, IsoDDE, and move its drug pipeline toward clinical trials.

IsoDDE aims to improve drug design predictions

IsoDDE stands for Isomorphic Drug Design Engine. According to Isomorphic Labs, it goes beyond AlphaFold 3 and aims to better predict drug binding and docking sites. The company was founded in 2021.

Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson. It has no approved drug yet. The size of the round puts substantial funding behind a platform and drug pipeline still being developed.

A researcher's gloved hands dispense droplets into an assay plate to prepare an early drug-binding experiment.
Illustration: AI & Tech News

Hassabis took a new role at Alphabet

Demis Hassabis leads Isomorphic Labs. He stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet’s Chief Scientist. Hassabis and John Jumper won the 2024 Nobel Prize in Chemistry for their work on AlphaFold.

Deepmind disbanded its original AlphaFold team in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely.

Deepmind released AlphaGenome 2 in early November 2026. It predicts how DNA variants affect gene activity in specific cell types. Isomorphic Labs’ next stated step is to advance IsoDDE and push its drug pipeline toward clinical trials.

What this means

Before its latest funding, Isomorphic Labs raised $2.1 billion in May 2026, the same month Google DeepMind CEO Demis Hassabis announced the Gemini for Science initiative targeting drug discovery. DeepMind subsequently disbanded its original AlphaFold team in July 2026, moving multiple researchers to Isomorphic Labs while nearly a quarter left DeepMind entirely. In August 2026, Hassabis stepped down from day-to-day DeepMind leadership to become Alphabet's Chief Scientist, and Isomorphic Labs joined DeepMind and Meta in October 2026 to invest $300 million into the Biohub nonprofit research organization.

Newsletter

Get the best AI & tech news daily

A concise daily digest. Unsubscribe anytime.

We use your email only to send this newsletter.

Keep reading